NCT02426372View on ClinicalTrials.gov

Safety and Efficacy of QBECO in Moderate to Severe Ulcerative Colitis

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Ulcerative Colitis
Interventions
BIOLOGICAL

QBECO SSI

QBECO Site Specific Immunomodulators

Trial Locations (3)

Unknown

University of Alberta, Edmonton

GI Research Institute, Vancouver

McMaster University, Hamilton

All Listed Sponsors
lead

Qu Biologics Inc.

INDUSTRY

NCT02426372 - Safety and Efficacy of QBECO in Moderate to Severe Ulcerative Colitis | Biotech Hunter | Biotech Hunter